Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: Andrew Patient

Merus Labs – targeting underdeveloped biopharma assets

Posted on by

Merus Labs is a biopharma company focused on acquiring established products to optimize the value of underdeveloped pharmaceutical assets.

Merus Labs – targeting underdeveloped biopharma assets

merus labs Continue reading →

Posted in Biotech Companies, Biotech Companies Canada | Tagged acenocoumarol, Andrew Patient, anticoagulant, anticoagulant Sintrom, Barry Fishman, Bob McLay, C. difficile, darifenacin, David Guebert, Emselex, Enablex, Geoff Morrow, Merus Labs, Merus Labs - targeting underdeveloped biopharma assets, Michael Cloutier, overactive bladder syndrome, pharmaceutical product, pharmaceutical products, product acquisition, Robert Pollock, Sintrom, targeting underdeveloped biopharma asset, targeting underdeveloped biopharma assets, Theresa Firestone, thromboembolic, thromboembolic diseases, Tim Sorenson, Ulrich Schoeberl, underdeveloped pharmaceutical asset, underdeveloped pharmaceutical assets, Vancocin, vancomycin, vitamin K

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress